A study showed that using measurable residual disease (MRD) to guide ibrutinib-venetoclax therapy significantly improved progression-free survival in chronic lymphocytic leukemia (CLL) compared with ...

This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment adherence patterns, patient symptom assessment, research on treatment ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of cases, patients with CLL will develop lymphoma, a complication known as ...

How well a certain treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) works can vary greatly depending on the makeup of an individual patient’s disease, making ...

Lori A. Leslie, MD, and Hoshiyuki Iida, APN, offer closing thoughts on the future treatment landscape of chronic lymphocytic leukemia. Lori A. Leslie, MD: We’ve talked a lot about how this landscape ...

In the age of targeted therapy, what’s the best long-term strategy to treat chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries? Should treatment be continuous to achieve ...

Current and emerging treatments for relapsed or refractory CLL show promise, with outcomes expected to improve beyond current data. Treatment responses in CLL can last for years, especially in ...

“This study demonstrates that a PA intervention utilizing aerobic exercise can increase leisure time PA and decrease fatigue in older adult patients with CLL, and that these changes are correlated to ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that causes your bone marrow to make too many of a type of white blood cells called lymphocytes. Unlike other types of leukemia, it’s a ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...